Showing results (91-100 of 175) with videos related to

Sort By:
Pageof 18
Molecular Cancer Therapeutics|June 23, 2021
SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve <i>ALK-, ROS1-</i>, or <i>EGFR</i>-altered Non-small Cell Lung CancerHirohisa Kano, Eiki Ichihara, Hiromi Watanabe, et al.
Cancer Science|July 30, 2020
Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance statusHirohisa Kano, Eiki Ichihara, Daijiro Harada, et al.
Cancer Research|January 1, 2016
Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine KinasesHideko Isozaki, Eiki Ichihara, Nagio Takigawa, et al.
Cancer Research|April 19, 2017
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung CancerEiki Ichihara, David Westover, Catherine B Meador, et al.
Clinical Lung Cancer|November 17, 2016
Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study ProtocolKiichiro Ninomiya, Eiki Ichihara, Katsuyuki Hotta, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2016
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experienceNaohiro Oda, Katsuyuki Hotta, Hiroshige Yoshioka, et al.
Clinical Lung Cancer|July 9, 2017
Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary FibrosisKohei Otsubo, Junji Kishimoto, Hirotsugu Kenmotsu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2012
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancerKatsuyuki Hotta, Etsuji Suzuki, Massimo Di Maio, et al.
Japanese Journal of Clinical Oncology|May 16, 2019
The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancerHiromi Watanabe, Toshio Kubo, Kiichiro Ninomiya, et al.
Oncology Reports|March 29, 2007
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cellsNagio Takigawa, Masami Takeyama, Toshiyuki Kozuki, et al.
Pageof 18